Gifford Bioscience

Gifford Bioscience is a specialized preclinical CRO offering expert services in receptor pharmacology and occupancy, a critical niche in early-stage drug discovery. Founded in 2020, the company leverages a team of PhD-level scientists and a suite of gold-standard techniques, including radioligand binding, autoradiography, and SPR (Biacore), to support client programs in neurology, oncology, and metabolic diseases. Its business model is entirely service-based, generating revenue by providing customized assay development and testing using human and animal tissues, cultured cells, and recombinant proteins. The company appears to be a privately held, revenue-generating entity capitalizing on the growing demand for sophisticated preclinical outsourcing.

A suite of receptor pharmacology and occupancy techniques including radioligand binding assays, receptor autoradiography, cellular uptake/release assays, Surface Plasmon Resonance (SPR/Biacore), and functional assays. Utilizes both gold-standard radiometric methods and advanced label-free kinetic affinity techniques.

Competes in the fragmented preclinical CRO market. Faces competition from large, diversified players (e.g., Charles River, Labcorp, Eurofins) that offer receptor pharmacology as part of broad portfolios, and from smaller, specialist CROs focusing on specific techniques or disease areas. Differentiation is based on deep scientific expertise, customization, and a focus on a specific methodological niche (receptor pharmacology/occupancy).